Editors' ChoiceCancer

p53 and Tumor Angiogenesis

See allHide authors and affiliations

Science's STKE  22 Aug 2006:
Vol. 2006, Issue 349, pp. tw287
DOI: 10.1126/stke.3492006tw287

The tumor suppressor protein p53 transcriptionally activates genes that control cell cycle arrest, apoptosis, and other cellular processes that help to prevent tumor development. Teodoro et al. now show that p53 appears to keep tumors in check by activating the gene encoding α(II) collagen prolyl-4-hydroxylase. This enzyme is required for the extracellular release of collagen-derived peptides, such as endostatin and tumstatin, that are potent inhibitors of tumor angiogenesis. The p53 gene is inactivated in many human cancers, presumably leading to reduced production of endogenous antiangiogenic peptides that defend against tumor growth.

J. G. Teodoro, A. E. Parker, X. Zhu, M. R. Green, p53-Mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313, 968-971 (2006). [Abstract] [Full Text]

Stay Connected to Science Signaling